BD&L strategy for oncology leadership
Over the last decade, oncology revenue growth for top pharma players has largely been driven by BD&L. Our experts take a deep dive into the growing oncology market uncovering the top drivers and activities of revenue growth.
Explore the full analysis, takeaways, and strategic recommendations for how to engage in BD&L to drive growth in oncology.
Contact us.
To speak with our experts, fill out the form below.
Jump to a slide with the slide dots.
Clement Francois
Navigating the Joint Clinical Assessment (JCA) with a strategic market access partner
Navigate the JCA launch with Putnam's expert strategies. Unlock optimal market access with PICO-driven insights, evidence plans & regulatory synergy.
Read moreKey outcomes of ASCO24
Our experts shared key themes for #ASCO24 and now summarize the vital insights on antibody drug conjugates, radiopharmaceuticals, and bispecifics.
Read moreThe expanding concept of value – Implications for manufacturers and payers
Micro-tutorial on payer value drivers, tackling challenges in their integration into payer/HTA frameworks and generating robust supporting evidence.
Read more